ImmunoGen, Inc. Announces Webcast of Presentations at Two Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 2, 2009-- ImmunoGen, Inc. (Nasdaq: IMGN) today announced the live webcast of its corporate presentations at two upcoming investor conferences.
Its presentation at the Thomas Weisel Partners Healthcare Conference 2009 is scheduled to begin at 3:15 p.m. EDT on September 9, 2009, and will take place at the Four Seasons Hotel Boston in Boston, Massachusetts. The live webcast can be accessed through the “Investor Information” section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the site until September 16, 2009.
Its presentation at the Robert W. Baird & Co. 2009 Health Care Conference is scheduled to begin at 9:30 a.m. EDT on September 10, 2009, and will take place at the Four Seasons Hotel New York in New York City. The live webcast of this presentation can be accessed through the ImmunoGen website in the same way. Following the live webcast, a replay of the presentation will be available at the site until September 17, 2009.
Daniel M. Junius, President and Chief Executive Officer of ImmunoGen, will be presenting an update on the Company at both conferences.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
Source: ImmunoGen, Inc.
Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
